---
title: "Incannex Healthcare Inc. (IXHL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IXHL.US.md"
symbol: "IXHL.US"
name: "Incannex Healthcare Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T16:49:18.186Z"
locales:
  - [en](https://longbridge.com/en/quote/IXHL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IXHL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IXHL.US.md)
---

# Incannex Healthcare Inc. (IXHL.US)

## Company Overview

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease. Incannex Healthcare Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.incannex.com](https://www.incannex.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: D (0.70)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 147 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -122.68% |  |
| P/B Ratio | 0.69 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 51842427.00 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -117.18% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -122.68% | E |
| Total Assets YoY | 395.67% | A |
| Net Assets YoY | 916.26% | A |
| Cash Flow Margin | 36.61% | D |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 6.29% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Incannex Healthcare Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-122.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.69",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "51842427.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-117.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-122.68%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "395.67%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "916.26%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "36.61%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "6.29%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.07 | 109/190 | - | - | - |
| PB | 0.69 | 27/190 | 7.44 | 1.88 | 0.81 |
| PS (TTM) | 7764.11 | - | 9039.37 | 7764.11 | 422.59 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-18T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.63 |
| Highest Target | 1409.13 |
| Lowest Target | 1409.13 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IXHL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IXHL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IXHL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IXHL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**